Cost-effectiveness is an important consideration when treating HIT. This is because alternative anticoagulants (other than<unk>  can be quite expensive given their unique mechanisms of action and the costs of drug development. It has been shown that fondaparinux is the most cost-effective treatment for HIT, compared to direct thrombin inhibitors.
Heparin-induced thrombocytopenia cost-effectiveness of therapy
Heparin-induced thrombocytopenia future or investigational therapies
Thrombophilia cost-effectiveness of therapy
Heparin-induced thrombocytopenia primary prevention
Tumor lysis syndrome cost-effectiveness of therapy
Antiphospholipid syndrome primary prevention
Thrombophilia secondary prevention
Thrombophilia primary prevention